The groundbreaking therapy of the medication represents a major development in the handling of type 2 diabetes. Different to existing therapies, tirzepatide affects dual pathways – glucagon-like peptide-1 (GLP-1) and https://tirzepatide-peptide930044.ssnblog.com/40585013/tirzepatide-peptide-a-new-frontier-in-diabetes-treatment